Browsing by author "Marsden,"
Now showing items 21-40 of 112
-
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.
Brown, JS; Sundar, R; Lopez, J (2018-02)The idea that chemotherapy can be used in combination with immunotherapy may seem somewhat counterproductive, as it can theoretically eliminate the immune cells needed for antitumour immunity. However, much preclinical ... -
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.
Smith, I; Yardley, D; Burris, H; De Boer, R; Amadori, D; et al. (2017-04)Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive ... -
Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer.
Sclafani, F; Brown, G; Cunningham, D; Wotherspoon, A; Mendes, LST; et al. (2017-11)Background Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer.Methods mrTRG and pTRG were compared in rectal cancer patients from two phase ... -
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Neoptolemos, JP; Palmer, DH; Ghaneh, P; Psarelli, EE; Valle, JW; et al. (2017-03)Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. ... -
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn, C; Snee, M; Ashcroft, L; Appel, W; Barlesi, F; et al. (2017-08)Background Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard ... -
Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients.
Matoori, S; Thian, Y; Koh, D-M; Sohaib, A; Larkin, J; et al. (2017-08)The first-line therapy in metastatic renal cell carcinoma (mRCC), sunitinib, exhibits an objective response rate of approximately 30%. Therapeutic alternatives such as other tyrosine kinase inhibitors, VEGF inhibitors, or ... -
Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.
Lawler, M; Alsina, D; Adams, RA; Anderson, AS; Brown, G; et al. (BMJ PUBLISHING GROUP, 2018-01-01)OBJECTIVE: Colorectal cancer (CRC) leads to significant morbidity/mortality worldwide. Defining critical research gaps (RG), their prioritisation and resolution, could improve patient outcomes. DESIGN: RG analysis was ... -
Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.
Stewart, GD; Aitchison, M; Bex, A; Larkin, J; Lawless, C; et al. (2017-06)Despite great interest, two randomised controlled trials (RCTs) of cytoreductive nephrectomy in the tyrosine kinase inhibitor setting in metastatic renal cell carcinoma have either closed early (SURTIME) or are recruiting ... -
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long, GV; Flaherty, KT; Stroyakovskiy, D; Gogas, H; Levchenko, E; et al. (2017-07)Background Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in BRAF ... -
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.
Sclafani, F; Kim, TY; Cunningham, D; Kim, TW; Tabernero, J; et al. (2017-01)Limited data are available on the efficacy of anti-IGF-1R agents in KRAS mutant colorectal cancer (CRC). We analysed the outcome of 69 chemorefractory, KRAS exon 2 mutant CRC patients who were enrolled in a double-blind, ... -
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
George, A; Kaye, S; Banerjee, S (2017-05)The treatment of patients with ovarian cancer is rapidly changing following the success of poly [ADP-ribose] polymerase (PARP) inhibitors in clinical trials. Olaparib is the first PARP inhibitor to be approved by the EMA ... -
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
Ahmed, HU; El-Shater Bosaily, A; Brown, LC; Gabe, R; Kaplan, R; et al. (2017-02)Background Men with high serum prostate specific antigen usually undergo transrectal ultrasound-guided prostate biopsy (TRUS-biopsy). TRUS-biopsy can cause side-effects including bleeding, pain, and infection. Multi-parametric ... -
Diagnostic accuracy of the PROMIS study - Authors' reply.
Ahmed, HU; Brown, LC; Kaplan, R; Parker, C; Emberton, M (2017-07) -
Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?
Lubberman, FJE; Gelderblom, H; Wilmer, CM; Kweekel, DM; Desar, IME; et al. (2017-10) -
Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force.
Stokke, C; Gabiña, PM; Solný, P; Cicone, F; Sandström, M; et al. (2017-11-21)BACKGROUND:The European directive on basic safety standards (Council directive 2013/59 Euratom) mandates dosimetry-based treatment planning for radiopharmaceutical therapies. The directive comes into operation February ... -
EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems.
Kaalep, A; Sera, T; Oyen, W; Krause, BJ; Chiti, A; et al. (2018-03)PURPOSE:From 2010 until July 2016, the EANM Research Ltd. (EARL) FDG-PET/CT accreditation program has collected over 2500 phantom datasets from approximately 200 systems and 150 imaging sites worldwide. The objective of ... -
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.
Shah, MA; Bang, Y-J; Lordick, F; Alsina, M; Chen, M; et al. (2017-05)Importance Dysregulation of the mesenchymal-epithelial transition (MET) signaling pathway is associated with poor prognosis in gastroesophageal adenocarcinoma (GEC). We report results of METGastric, a phase 3 trial of the ... -
Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.
Parker, C; Zhan, L; Cislo, P; Reuning-Scherer, J; Vogelzang, NJ; et al. (2017-01)Symptomatic skeletal events (SSEs) commonly occur in patients with bone metastases, often leading to hospitalisations and decreased quality-of-life. In the ALSYMPCA trial, radium-223 significantly improved overall survival ... -
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
D'Angelo, SP; Larkin, J; Sosman, JA; Lebbé, C; Brady, B; et al. (2017-01)Purpose Mucosal melanoma is an aggressive malignancy with a poor response to conventional therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint inhibitor), alone or combined with ipilimumab (a ... -
Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients.
Farag, S; van Coevorden, F; Sneekes, E; Grunhagen, DJ; Reyners, AKL; et al. (2017-11)Objective Although gastrointestinal stromal tumours (GIST) predominantly occur in older patients, data on treatment patterns in elderly GIST patients are scarce.Methods Patients registered in the Dutch GIST Registry (DGR) ...